LUIGI FERRUCCI, M.D.
Osteopathic Medicine at Hanover St, Baltimore, MD
License number
Maryland D-0048408
Category
Osteopathic Medicine
Type
General Practice
Address
Address
3001 S Hanover St FLOOR 5TH, Baltimore, MD 21225
Phone
(410) 350-3936
Personal information
See more information about LUIGI FERRUCCI at radaris.comName
Address
Phone
619 W University Pkwy, Baltimore, MD 21210
619 University Pkwy, Baltimore, MD 21210
Professional information
Senior Investigator At Nih
Position:
Senior Investigator at NIH
Location:
Baltimore, Maryland Area
Industry:
Government Administration
Work:
NIH
-
Senior Investigator
Luigi Ferrucci, Brooklyn MD
Specialties:
Family Physician
Address:
3001 S Hanover St, Brooklyn, MD 21225
Methods For Evaluating Osteoarthritis Risk
US Patent:
2010015, Jun 17, 2010
Filed:
Dec 24, 2009
Appl. No.:
12/647166
Inventors:
Shari M. Ling - Ellicott City MD, US
Lorah Perlee - Wilton CT, US
Velizar T. Tchernev - Sofia, BG
Dhavalkumar D. Patel - Chapel Hill NC, US
Luigi Ferrucci - Baltimore MD, US
Ming Zhan - Germantown MD, US
Lorah Perlee - Wilton CT, US
Velizar T. Tchernev - Sofia, BG
Dhavalkumar D. Patel - Chapel Hill NC, US
Luigi Ferrucci - Baltimore MD, US
Ming Zhan - Germantown MD, US
International Classification:
A61K 49/00, C12Q 1/68, C40B 30/04, C40B 40/10, G01N 33/68, A61K 31/7008, A61K 31/60, A61K 31/192, A61K 31/4025, A61K 31/167, A61K 31/737, A61K 31/65
US Classification:
424 91, 435 6, 506 9, 506 18, 435 71, 514 62, 514165, 514570, 514569, 514411, 514629, 514 54, 514152
Abstract:
Methods are provided for evaluating osteoarthritis (OA), for example for diagnosing OA, to confirm a diagnosis of OA, to assess or prognose progression of OA, determining the severity of a subject who has OA, and determining a subject's risk of developing OA in the future, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes determining an amount of activity (such as an amount of protein present or an amount of expression) of OA risk-related molecules, such as soluble vascular adhesion protein 1 (sVAP-1) or interleukin-15 (IL-15). Also provided are methods of identifying one or more compounds that alter the activity of an OA-related molecule, thereby identifying potential anti-osteoarthritis drugs.
Biomarkers For Osteoarthritis
US Patent:
2007022, Sep 27, 2007
Filed:
Aug 12, 2005
Appl. No.:
11/573711
Inventors:
Shari Ling - Ellicott City MD, US
Lorah Perlee - Wilton CT, US
Velizar Tchernev - Sofia, BG
Dhavalkumar Patel - Chapel Hill NC, US
Luigi Ferrucci - Baltimore MD, US
Ming Zhan - Germantown MD, US
Lorah Perlee - Wilton CT, US
Velizar Tchernev - Sofia, BG
Dhavalkumar Patel - Chapel Hill NC, US
Luigi Ferrucci - Baltimore MD, US
Ming Zhan - Germantown MD, US
International Classification:
G01N 33/68
US Classification:
514002000, 435006000, 435007100
Abstract:
Methods are provided for evaluating osteoarthritis (OA), for example for diagnosing OA, to confirm a diagnosis of OA, to assess or prognose progression of OA, determining the severity of a subject who has OA, and determining a subject's risk of developing OA in the future, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes determining an amount of activity (such as an amount of protein present or an amount of expression) of OA risk-related molecules, such as soluble vascular adhesion protein 1 (sVAP-1) or interleukin-15 (IL-15). Also provided are methods of identifying one or more compounds that alter the activity of an OA-related molecule, thereby identifying potential anti-osteoarthritis drugs.